doi: 10.1038/nrd2572.
The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential
Affiliations
- PMID: 18670432
- DOI: 10.1038/nrd2572
Item in Clipboard
The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential
Nat Rev Drug Discov.
2008 Aug.
Abstract
Identification of the enigmatic nociceptin/orphanin FQ peptide (N/OFQ) in 1995 represented the first successful use of reverse pharmacology and led to deorphanization of the N/OFQ receptor (NOP). Subsequently, the N/OFQ-NOP system has been implicated in a wide range of biological functions, including pain, drug abuse, cardiovascular control and immunity. Although this could be considered a hurdle for the development of pharmaceuticals selective for a specific disease indication, NOP represents a viable drug target. This article describes potential clinical indications and highlights the current status of the very limited number of clinical trials.
Similar articles
-
The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.Pharmacol Ther. 2014 Mar;141(3):283-99. doi: 10.1016/j.pharmthera.2013.10.011. Epub 2013 Nov 1. Pharmacol Ther. 2014. PMID: 24189487 Free PMC article. Review.
-
Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder.Br J Pharmacol. 2015 Jan;172(2):571-82. doi: 10.1111/bph.12701. Epub 2014 Jul 1. Br J Pharmacol. 2015. PMID: 24666365 Free PMC article.
-
Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.Curr Drug Targets. 2007 Jan;8(1):117-35. doi: 10.2174/138945007779315605. Curr Drug Targets. 2007. PMID: 17266536 Review.
-
Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain.Molecules. 2022 Jan 18;27(3):595. doi: 10.3390/molecules27030595. Molecules. 2022. PMID: 35163856 Free PMC article. Review.
-
Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy?J Pharmacol Exp Ther. 2003 Aug;306(2):423-9. doi: 10.1124/jpet.102.046979. Epub 2003 Apr 29. J Pharmacol Exp Ther. 2003. PMID: 12721334
Cited by
-
Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys.Br J Pharmacol. 2015 Jul;172(14):3661-70. doi: 10.1111/bph.13150. Epub 2015 May 12. Br J Pharmacol. 2015. PMID: 25828800 Free PMC article.
-
Opioid-related (ORL1) receptors are enriched in a subpopulation of sensory neurons and prolonged activation produces no functional loss of surface N-type calcium channels.J Physiol. 2012 Apr 1;590(7):1655-67. doi: 10.1113/jphysiol.2012.228429. Epub 2012 Feb 27. J Physiol. 2012. PMID: 22371475 Free PMC article.
-
In vitro sepsis induces Nociceptin/Orphanin FQ receptor (NOP) expression in primary human vascular endothelial but not smooth muscle cells.PLoS One. 2022 Sep 15;17(9):e0274080. doi: 10.1371/journal.pone.0274080. eCollection 2022. PLoS One. 2022. PMID: 36107872 Free PMC article.
-
Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore.ACS Chem Neurosci. 2010 Feb 17;1(2):155-164. doi: 10.1021/cn900025j. ACS Chem Neurosci. 2010. PMID: 20352071 Free PMC article.
-
Copper-Mediated Radiocyanation of Unprotected Amino Acids and Peptides.J Am Chem Soc. 2022 Apr 27;144(16):7422-7429. doi: 10.1021/jacs.2c01959. Epub 2022 Apr 18. J Am Chem Soc. 2022. PMID: 35437016 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
